D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dizal Jiangsu Pharmaceutical Co Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Accounts Receivables
ÂĄ48m
CAGR 3-Years
91%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Accounts Receivables
ÂĄ2.5B
CAGR 3-Years
86%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Accounts Receivables
ÂĄ3B
CAGR 3-Years
63%
CAGR 5-Years
74%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Accounts Receivables
ÂĄ949.9m
CAGR 3-Years
26%
CAGR 5-Years
3%
CAGR 10-Years
25%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Accounts Receivables
ÂĄ25.5B
CAGR 3-Years
43%
CAGR 5-Years
44%
CAGR 10-Years
51%
Imeik Technology Development Co Ltd
SZSE:300896
Accounts Receivables
ÂĄ206.1m
CAGR 3-Years
91%
CAGR 5-Years
87%
CAGR 10-Years
N/A
No Stocks Found

Dizal Jiangsu Pharmaceutical Co Ltd
Glance View

Market Cap
18.4B CNY
Industry
Biotechnology

Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.

Intrinsic Value
30.31 CNY
Overvaluation 33%
Intrinsic Value
Price
D

See Also

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Receivables?
Accounts Receivables
48m CNY

Based on the financial report for Dec 31, 2023, Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Receivables amounts to 48m CNY.

What is Dizal Jiangsu Pharmaceutical Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
17%

The average annual Accounts Receivables growth rates for Dizal Jiangsu Pharmaceutical Co Ltd have been 91% over the past three years , 17% over the past five years .

Back to Top